Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells

Experimental and Therapeutic Medicine

Volumn 4, Issue 2, 2012, Pages 291-296

  Tai, De Jun ^a   Jin, Wen Sen ^a   Wu, Cheng Si ^a   Si, Hong Wei ^a   Cao, Xian Dong ^a   Guo, Ai Jun ^a   Chang, Jia Cong ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Gastric adenocarcinoma cells; Glutathione; Multidrug resistance; Redox status

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5,5' DITHIOBIS(2 NITROBENZOIC ACID); ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CISPLATIN; FLUOROURACIL; GLUTATHIONE; MITOMYCIN;

ARTICLE; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MULTIDRUG RESISTANCE; OXIDATION REDUCTION STATE; STOMACH ADENOCARCINOMA; TUMOR MICROENVIRONMENT;

EID: 84862658808     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.591     Document Type: Article

References (51)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 870-873, 1999.
2. Alberts SR, Cervantes A and van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14 (Suppl 2): 31-36, 2003.
3. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD and Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results from the global burden of disease 2000. BMC Cancer 2: 37, 2002.
4. Meads MB, Hazlehurst LA and Dalton WS: The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14: 2519-2526, 2008.
5. Parmar K, Mauch P, Vergilio JA, Sackstein R and Down JD: Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104: 5431-5436, 2007.
6. Glimelius B, Ekström K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
7. Hill ME and Cunningham D: Medical management of advanced gastric cancer. Cancer Treat Rev 24: 113-118, 1998.
8. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
9. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
10. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E and Murray GI: Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res 10: 3237-3248, 2004.
11. Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Moscow) 65: 95-106, 2000.
12. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587: 164-173, 2002.
13. Larsen AK, Escargueil AE and Skladanowski A: Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85: 217-229, 2000.
14. Ross DD: Novel mechanisms of drug resistance in leukemia. Leukemia 14: 467-473, 2000.
15. Litman T, Druley TE, Stein WD and Bates SE: From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001.
16. Narasaki F, Oka M, Nakano R, Ikeda K, Fukuda M, Nakamura T, Soda H, Nakagawa M, Kuwano M and Kohno S: Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem Biophys Res Commun 240: 606-611, 1997.
17. Nakamura T, Oka M, Aizawa K, Soda H, Fukuda M, Terashi K, Ikeda K, Mizuta Y, Noguchi Y, Kimura Y, et al: Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. Biochem Biophys Res Commun 255: 618-624, 1999.
18. Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H, Ikeda K, Terashi K, Matsuo I, Soda H, et al: The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res 87: 1263-1270, 1996.
19. Hao Z, Li X, Qiao T, Du R, Hong L and Fan D: CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol Ther 5: 261-266, 2006.
20. Maeda S, Sugiura T, Saikawa Y, Kubota T, Otani Y, Kumai K and Kitajima M: Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 95: 679-684, 2004.
21. Tang XQ, Bi H, Feng JQ and Cao JG: Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 26: 1009-1016, 2005.
22. Chen Y, Ji L, Wang H and Wang Z: Intracellular glutathione plays important roles in pyrrolizidine alkaloids-induced growth inhibition on hepatocytes. Environ Toxicol Pharmacol 28: 357-362, 2009.
23. Kosower NS and Kosower EM: The glutathione status of cells. Int Rev Cytol 54: 109-160, 1978.
24. Markman M: Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci 10: 515-519, 2008.
25. Muggia F: Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112: 275-281, 2009.
26. Lustberg MB and Edelman MJ: Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 8: 38-46, 2007.
27. Matthews GM, Howarth GS and Butler RN: Nutrient and antioxidant modulation of apoptosis in gastric and colon cancer cells. Cancer Biol Ther 5: 569-572, 2006.
28. Podder S, Chattopadhyay A, Bhattacharya S, Ray MR and Chakraborty A: Fluoride-induced genotoxicity in mouse bone marrow cells: effect of buthionine sulfoximine and N-acetyl-L-cysteine. J Appl Toxicol 31: 618-625, 2011.
29. Beketić-Oresković L, Osmak M and Jaksić M: Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): mechanisms involved in the resistance. Neoplasma 41: 163-169, 1994.
30. Balendiran GK, Dabur R and Fraser D: The role of glutathione in cancer. Cell Biochem Funct 22: 343-352, 2004.
31. Akiyama SI, Chen ZS, Sumizawa T and Furukawa T: Resistance to cisplatin. Anticancer Drug Des 14: 143-151, 1999.
32. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A and Aloyz R: Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7: 454-461, 2001.
33. Bredel M: Anticancer drug resistance in primary human brain tumors. Brain Res Rev 35: 161-204, 2001.
34. Germann UA: P-glycoprotein - a modulator of multidrug resistance in tumor cells (Review). Eur J Cancer 32A: 927-944, 1996.
35. Müller M, Meijer C, Zaman GJ, et al: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033-13037, 1994.
36. Hipfner DR, Deeley RG and Cole SP: Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359-376, 1999.
37. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
38. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
39. Kang YH, Lee E, Youk HJ, Kim SH, Lee HJ, Park YG and Lim SJ: Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. Cancer Lett 217: 181-190, 2005.
40. Jin J, Huang M, Wei HL and Liu GT: Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol 8: 1029-1034, 2002.
41. Xu BH and Singh SV: Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Cancer Res. 52: 6666-6670, 1992.
42. Chen HH and Kuo MT: Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010 pii: 430939, 2010.
43. Akan I, Akan S, Akca H, Savas B and Ozben T: Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell Int 5: 22, 2005.
44. Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK and Chen GF: Regulation of hypoxia inducible factor-1α expression by the alteration of redox status in HepG2 cells. J Exp Clin Cancer Res 30: 61, 2011.
45. Franco R and Cidlowski JA: Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16: 1303-1314, 2009.
46. Akan I, Akan S, Akca H, Savas B and Ozben T: N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance. Eur J Clin Invest 34: 683-689, 2004.
47. Chuman Y, Chen ZS, Seto K, et al: Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett 129: 69-76, 1998.
48. Schafer FQ and Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biol Med 30: 1191-1212, 2001.
49. Commandeur JN, Stijntjes GJ and Vermeulen NP: Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxification mechanisms in xenobiotics. Pharmacol Rev 47: 271-330, 1995.
50. Benderra Z, Trussardi A, Morjani H, Villa AM, Doglia SM and Manfait M: Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer 36: 428-434, 2000.
51. Han YH, Moon HJ, You BR, Kim SZ, Kim SH and Park WH: The effects of N-acetyl cysteine on the MG132 proteasome inhibitor-treated lung cancer cells in relation to cell growth, reactive oxygen species and glutathione. Int J Mol Med 25: 657-62, 2010.